#SanBio

Operating income for the fiscal year ending January 2026 was a loss of 3,794 million JPY, and net income was a loss of 3,842 million JPY, worsening by 278 million JPY and 960 million JPY year-over-year respectively. Approximately 16.2 billion JPY of growth capital was secured through new share issuance and other means.

SanBio Inc. has finalized the allocation of 75,000 stock options (equivalent to 75,000 common shares, exercise price 1,898 yen) resolved on January 9, 2026, to 3 employees.

SanBio Inc. plans to allocate a total of 75,000 subscription rights to shares to 3 employees on January 27, 2026. The exercise period is until January 8, 2036.